geroFarma
ActiveSummary
geroFarma has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €240,699 and a net result of €107,225. Equity is growing by ~66.7% per year across the filed fiscal years. Its solvency ranks better than 34% of 12386 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).
History
Acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
11-07
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
31-12
Financial
Highest result since 2022net €107,225 ▲98.5%
Operating result €173,980, net result €107,225, both a record.
31-12
Financial
Equity above €200,000Eq €240,699 ▲80.3%
4 profitable years in a row build equity to €240,699.
11-07
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
31-12
Financial
Equity above €100,000Eq €133,474 ▲68%
3 profitable years in a row build equity to €133,474.
17-07
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
31-12
Financial
Liquidity times 6current ratio 1.01
Current ratio from 0.17 to 1.01; short-term debt falls from €147,756 to €117,179.
24-07
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 3 acts read
About the unread acts
We know of 3 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.